ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

IRWD Ironwood Pharmaceuticals Inc

3.56
0.00 (0.00%)
13 Dec 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Ironwood Pharmaceuticals Inc NASDAQ:IRWD NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 3.56 3.32 3.69 0 00:00:00

Ironwood Pharmaceuticals to Participate in the Jefferies London Healthcare Conference

13/11/2024 9:01pm

Business Wire


Ironwood Pharmaceuticals (NASDAQ:IRWD)
Historical Stock Chart


From Dec 2024 to Dec 2024

Click Here for more Ironwood Pharmaceuticals Charts.

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that Sravan Emany, Chief Operating Officer and Chief Financial Officer, will participate in a fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024 at 7:30 a.m. GT at the Waldorf Hilton in London.

A live webcast of Ironwood’s fireside chat will be accessible through the Investors section of the company’s website at www.ironwoodpharma.com. A replay of the webcast will be available on Ironwood’s website for 1 year following the conference.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals (Nasdaq: IRWD), an S&P SmallCap 600® company, is a leading gastrointestinal (GI) healthcare company on a mission to advance the treatment of GI diseases and redefine the standard of care for GI patients. We are pioneers in the development of LINZESS® (linaclotide), the U.S. branded prescription market leader for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). LINZESS is also approved for the treatment of functional constipation in pediatric patients ages 6-17 years-old. Ironwood is also advancing apraglutide, a next-generation, long-acting synthetic GLP-2 analog being developed for rare gastrointestinal diseases, including short bowel syndrome with intestinal failure (SBS-IF), as well as several earlier stage assets. Building upon our history of GI innovation, we keep patients at the heart of our R&D and commercialization efforts to reduce the burden of GI diseases and address significant unmet needs.

Founded in 1998, Ironwood Pharmaceuticals is headquartered in Boston, Massachusetts, with a site in Basel, Switzerland.

We routinely post information that may be important to investors on our website at www.ironwoodpharma.com. In addition, follow us on X and on LinkedIn.

Investors: Greg Martini, 617-374-5230 gmartini@ironwoodpharma.com

Matt Roache, 617-621-8395 mroache@ironwoodpharma.com

Media: Beth Calitri, 978-417-2031 bcalitri@ironwoodpharma.com

1 Year Ironwood Pharmaceuticals Chart

1 Year Ironwood Pharmaceuticals Chart

1 Month Ironwood Pharmaceuticals Chart

1 Month Ironwood Pharmaceuticals Chart

Your Recent History

Delayed Upgrade Clock